Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Department of Medicine, University of Illinois, Chicago, Illinois; Division of Genetic Epidemiology, University of Utah, Salt Lake City, Utah; National Human Genome Research Institute, NIH; and Department of Urology and Oncology, Johns Hopkins Medical Institutions, Baltimore, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, and Core Genotyping Facility, SAIC-Frederick, Inc., National Cancer Institute, NIH, DHHS, Gaithersburg; and Genome Technology Branch, National Human Genome Research Institute, NIH; and Cancer Genetics Branch, National Human Genome Research Institute, Bethesda, Maryland; Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan; Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom; and The Institute of Cancer Research, Surrey, and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, and Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, and The Broad Institute, Cambridge, Massachusetts; deCODE Genetics, Inc., Reykjavik, Iceland; Center for Clinical Epidemiology and Biostatistics, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; and Departments of Epidemiology and Biostatistics, and Urology, Institute for Human Genetics, University of California, San Francisco, California.
Compelling evidence supports a genetic component to prostate cancer susceptibility and aggressiveness. Recent genome-wide association studies have identified more than 30 single-nucleotide polymorphisms associated with prostate cancer susceptibility. It remains unclear, however, whether such genetic variants are associated with disease aggressiveness-one of the most important questions in prostate cancer research today. To help clarify this and substantially expand research in the genetic determinants of prostate cancer aggressiveness, the first National Cancer Institute Prostate Cancer Genetics Workshop assembled researchers to develop plans for a large new research consortium and patient cohort. The workshop reviewed the prior work in this area and addressed the practical issues in planning future studies. With new DNA sequencing technology, the potential application of sequencing information to patient care is emerging. The workshop, therefore, included state-of-the-art presentations by experts on new genotyping technologies, including sequencing and associated bioinformatics issues, which are just beginning to be applied to cancer genetics.
Written by:
Catalona WJ, Bailey-Wilson JE, Camp NJ, Chanock SJ, Cooney KA, Easton DF, Eeles RA, Fitzgerald LM, Freedman ML, Gudmundsson J, Kittles RA, Margulies EH, McGuire BB, Ostrander EA, Rebbeck TR, Stanford JL, Thibodeau SN, Witte JS, Isaacs WB. Are you the author?
Reference: Cancer Res. 2011 May 15;71(10):3442-3446.
doi: 10.1158/0008-5472.CAN-11-0314
PubMed Abstract
PMID: 21558387
UroToday.com Prostate Cancer Section
